Table 9.
Antiviral activity of 23 against a panel of HIV‐1 viral strains.
|
Virus |
IC50 [nm] values |
||||||
|---|---|---|---|---|---|---|---|
|
SQV |
RTV |
IDV |
NFV |
APV |
DRV |
23 |
|
|
HIV‐1ET |
17 |
15 |
30 |
32 |
23 |
n.d. |
3 |
|
HIV‐1B |
230 |
>1000 |
>1000 |
>1000 |
290 |
10.2 |
15 |
|
HIV‐1C |
100 |
>1000 |
500 |
310 |
300 |
3.5 |
5 |
|
HIV‐1G |
59 |
>1000 |
500 |
170 |
310 |
3.7 |
20 |
|
HIV‐1TM |
250 |
>1000 |
>1000 |
>1000 |
220 |
3.5 |
4 |
|
HIV‐1EV |
>1000 |
>1000 |
>1000 |
>1000 |
>1000 |
n.d. |
52 |
|
HIV‐1ES |
>1000 |
>1000 |
>1000 |
>1000 |
>1000 |
n.d. |
31 |
|
HIV‐1K |
20 |
58 |
260 |
>1000 |
68 |
3 |
3 |
[a] Amino acid substitutions identified in the protease‐encoding region of HIV‐1B (B), HIV‐1C (C), HIV‐1G (G), HIV‐1TM (TM), HIV‐1EV (EV), HIV‐1ES (ES), HIV‐1ET (ET), HIV‐1K (NFVR) as compared to the consensus B sequence cited from the Los Alamos data base. All values were determined in triplicate. The IC50 values were determined by employing PHA‐PBMC as target cells and the inhibition of p24 Gag protein production as the endpoint. See reference reference 51 for details.